Ro 08-2750 NLT 98%

Ro 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC₅₀ of ~ 1 µM. Ro 08-2750 inhibits NGF binding to p75^NTR selectively over TRKA^[1]. Ro 08-2750 is a selective _{MSI RNA-binding} activity inhibitor, with an IC₅₀ of 2.7 μM^[3]. IC50 & Target: IC50: ~1 µM (NGF)^[1], 2.7 μM (MSI RNA-binding)^[3] In Vitro: Ro 08-2750 binds to the NGF dimer thereby probably inducing a change in its conformation such that NGF cannot bind to p75^NTR anymore^[2].
Ro 08-2750 (10 nM) completely rescues cells from undergoing NGF-induced SK-N-MC 103 cells death^[2].
Ro 08-2750 (5-10 μM; 8 hours) increases differentiation and apoptosis in myeloid leukemia cells^[3].
Ro 08-2750 inhibits survival of human AML lines and patient cells^[3].
Ro 08-2750 inhibits MSI2 RNA-binding and alters MSI2 gene signature^[3].
In Vivo: Ro 08-2750 (13.75 mg/kg; i.p.) inhibits leukemogenesis in a myeloid leukemia model in vivo^[3].